Navigation Links
New Drug Promising Against Tough-to-Treat Kidney Cancer
Date:10/30/2007

Axitinib produced good responses in almost half of patients, study found

TUESDAY, Oct. 30 (HealthDay News) -- An experimental drug called axitinib shows promise for treating people with what's known as cytokine-refractory metastatic kidney cancer -- a group of patients who typically have a poor response to drug treatment.

Axitinib is a selective inhibitor of cancer-linked proteins known as vascular endothelial growth factor receptors 1, 2 and 3.

As reported in the November issue of The Lancet Oncology, the phase II study of 52 patients treated with the drug found that 23 patients had complete or partial responses (some of which were long lasting), and 12 of these patients progressed during the study, with a duration of response ranging from four months to 26 months.

The French researchers also found that 22 patients showed stable disease for longer than eight weeks, including 13 patients with stable disease for 24 weeks or longer.

Four patients had early disease progression, and 30 patients had high blood pressure related to the treatment. In general, side effects were manageable and controlled by dose modification or supportive care, the researchers said.

"The objective response and time to progression in our study suggest that axitinib might be a promising drug in the treatment of patients with metastatic renal-cell cancer, although a randomized controlled trial is needed to confirm this finding," study author Olivier Rixe, a professor in the department of medical oncology at the University of Paris, said in a prepared statement.

These findings "suggest that a drug such as axitinib has promise as a second-line treatment in cytokine-refractory metastatic renal-cell carcinoma and might have potential as first-line treatment or in combination with other agents," Dr. W. Marston Linehan of the U.S. National Cancer Institute, wrote in an accompanying comment.

More information

The U.S. National Cancer Institute has more about kidney cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Oct. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. ... Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at ... Maisel, founder of Retina Group of New York , is a Board ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... comprehensive treatment for eating disorders, is opening a brand new child and adolescent ... ages 8-17 and their families with even more specialized eating disorder treatment and ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... On May 23rd during the National Eye Institute’s “Healthy Vision Month”, Sharon ... honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon Kleyne is ... the Nile to fill their red clay pots with life-sustaining water.” Said Ashram co-founder ...
(Date:5/26/2016)... ... 2016 , ... Saint Francis Hospital & Medical Center has ... have paid off. Since implementation of these efforts, surgical errors and readmissions ... patient experiences and reduce costly complications. Since implementation in 2011, safety efforts have: ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
Breaking Medicine Technology: